TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06160271
Drug: PET scan of 68Ga-FAPI
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
Study: NCT06642428
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
Study: NCT05814354
Drug: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to label, as one option for Physician's Choice (determined before randomization).
Study: NCT05875168
Drug: DS-3939a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study: NCT06641284
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive Spironolactone as a part of their GDMT for Heart Failure
Study: NCT06637254
Drug: HSK31858
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
Study: NCT06637254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo comparator of study
Study: NCT04872270
Drug: Caffeine Pill
Normalized name: caffeine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
Study: NCT04872270
Drug: Percocet 10Mg-325Mg Tablet
Normalized name: Percocet 10mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: given postoperatively as standard post-op pain management
Study: NCT06022302
Drug: Diet + laxative
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.
Study: NCT04924660
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
Study: NCT04924660
Drug: TRV027
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
Study: NCT04924660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study: NCT05275855
Drug: EDI048
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Liquid
Study: NCT04987307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection.
Study: NCT05699811
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2, intravenous infusion every 4-6 weeks
Study: NCT06264141
Drug: Nitric Oxide Releasing Solution
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study: NCT06568367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken once daily
Study: NCT05722938
Drug: Trimodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP will be administered via IV infusion on 5 consecutive days
Study: NCT05722938
Drug: Placebo (human albumin 1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP will be administered via IV infusion on 5 consecutive days
Study: NCT05457556
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05457556
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04777396
Drug: Semagludtide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
Study: NCT04777396
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
Study: NCT06644417
Drug: TQA3605 tablets plus NAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQA3605 tablets is core protein regulator
Study: NCT05684731
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6.
Study: NCT06644417
Drug: TQA3605 Placebo plus NAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without drug substance
Study: NCT06644534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pearlitol® 100 SD (mannitol)
Study: NCT04914845
Drug: KPT-9274
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
Study: NCT04638517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT05587296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally once daily
Study: NCT05396859
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06200207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
Study: NCT05114265
Drug: OxyNorm
Normalized name: Oxynorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of OxyNorm
Study: NCT06643156
Drug: GP681 10mg/20mg/40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5/1/2×20mg power for oral suspension taken orally
Study: NCT06205407
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured at Viatris
Study: NCT06205407
Drug: Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured at Neolpharma.
Study: NCT05347693
Drug: Local standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local SoC in the country to be used as per local label
Study: NCT04895631
Drug: 18F-Fluorocholine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time injection of 4-7 millicurie (mCi)
Study: NCT05557812
Drug: eugenol based zinc oxide and Ferric Sulfate
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
Study: NCT06567470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05297786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT06576882
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
Study: NCT06577441
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05511909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Study: NCT04841200
Drug: Chinese medicine compound combined with symptomatic treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks.
Study: NCT04841200
Drug: Chinese medicine compound placebo combined with symptomatic treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks.
Study: NCT06345898
Drug: JWK002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal administration of gene therapy vector JWK002 to one eye.
Study: NCT05850546
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: guideline-recommended corticosteroid therapy
Study: NCT05026320
Drug: Naproxen gel
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10%, bid for 5 days (final application on morning of Day 6)
Study: NCT05026320
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.32% bid for 5 days (final application on morning of Day 6)
Study: NCT05026320
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid for 5 days (final application on morning of Day 6)
Study: NCT05666960
Drug: R-3750
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic
Study: NCT06435299
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Study: NCT06435299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
Study: NCT05409183
Drug: CRD-740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally.
Study: NCT05409183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally.
Study: NCT06795022
Drug: AZD9793 Subcutaneous (SC) monotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell-engaging antibody that targets GPC3 on tumour cells
Study: NCT05553366
Drug: HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT05553366
Drug: Placebo (matched to VX-548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-548 for oral administration.
Study: NCT05553366
Drug: Placebo (matched to HB/APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT05495243
Drug: ARINA-1
Normalized name: ZOSTERA MARINA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
Study: NCT05495243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9%)
Study: NCT05873686
Drug: NXP900
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXP900 is an orally administered SRC/YES1 kinase inhibitor
Study: NCT05697406
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
Study: NCT05030155
Drug: cyclophosphamide/azathioprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with FFS≥1 will receive cyclophosphamide then azathioprine
Study: NCT05030155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with FFS=0 will receive placebo
Study: NCT05948540
Drug: Intervention C Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Study: NCT01776996
Drug: Continued Access Arm
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
Study: NCT05142696
Drug: [68Ga]Ga-DOTA-TATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
Study: NCT05937152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
Study: NCT06639074
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given ID
Study: NCT05691699
Drug: Placebo for ABBV-903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; oral
Study: NCT06500299
Drug: HDM1002 200 mg QD 12weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM1002 tablets 200mg daily, 12weeks
Study: NCT06500299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided
Study: NCT05011266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo sub-lingual tablet daily
Study: NCT02677610
Drug: MSRD-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSRD-100 is a topical gel.
Study: NCT02677610
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle is a topical gel without the active ingredient in MSRD-100
Study: NCT05945823
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.
Study: NCT04516967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator tablet or sprinkle capsule
Study: NCT06343714
Drug: FB1003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT06343714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT05271708
Drug: Fespixon cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Study: NCT05271708
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
Study: NCT06020014
Drug: AZD4604
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4604
Study: NCT06050109
Drug: OFS continues to use group after 5 years use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
Study: NCT06310473
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m² po, Bid, d1-14, q3w ;
Study: NCT05371054
Drug: VIP152
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 12 cycles, or until disease progression or unacceptable toxicity
Study: NCT06025396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose comparator
Study: NCT05140863
Drug: HSK16149 20mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
Study: NCT05140863
Drug: HSK16149 40mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
Study: NCT05140863
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally twice a day, treatment period; 12-weeks fixed dose
Study: NCT06539455
Drug: standard anti-TB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
Study: NCT02645149
Drug: Matched targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
Study: NCT02645149
Drug: CDK4/6 and MEK inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib.
Study: NCT02645149
Drug: Compassionate Access Targeted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
Study: NCT05999435
Drug: LAU-7b for 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of14 days.
Study: NCT05999435
Drug: LAU-7b for 1 cycle, then placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of14 days.
Study: NCT05523895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin matching placebo
Study: NCT05805865
Drug: Conventional Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colgate Cavity Protection
Study: NCT05100251
Drug: WBC100 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type